Key result
Optimal medical therapy remains the AHA/ACC and ESC standard for secondary CAD prevention.
Why the study?
Differences exist between AHA/ACC and ESC guidelines for optimal medical therapy in obstructive coronary artery disease, alongside emerging medical therapies.
This review highlights the components of optimal medical therapy for secondary prevention in coronary artery disease, noting differences between major guidelines and pointing to emerging therapies.
Supports guideline-directed medical therapy for CAD secondary prevention; leaves open standardization across guidelines and integration of emerging therapies.
Coronary artery disease is a leading cause of mortality worldwide, and patients with obstructive coronary artery disease require optimal cardiovascular medical therapy along with lifestyle modification for secondary prevention of future cardiac events. Optimal medical therapy includes antiplatelet agents, high-intensity statins, beta-blockers, angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers, aldosterone antagonists, and calcium channel blockers. There are differences in the medical therapy guidelines of the American Heart Association/American College of Cardiology and the European Society of Cardiology. In addition, there are emerging medical therapies that may be added to future guidelines with additional cardiovascular outcome benefits.
No takes yet. Share an insight, caveat, or question.
Reed et al. (2022) conducted a review in Coronary artery disease. Optimal cardiovascular medical therapy was evaluated. Optimal cardiovascular medical therapy, including antiplatelets, statins, beta-blockers, and ACE inhibitors, is recommended by AHA/ACC and ESC guidelines for secondary prevention of coronary artery disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: